Talk:USA Drug Categories: Difference between revisions

Revision as of 10:20, 13 November 2014

((Talk Page}}

2014

Recent changes in pregnancy and lactation labeling: retirement of risk categories

Pharmacotherapy. 2014 Apr;34(4):389-95. doi: 10.1002/phar.1385. Epub 2014 Jan 4.

Ramoz LL1, Patel-Shori NM.

Abstract The rapid development and increased availability of novel pharmacologic therapies and pharmaceutical products has amplified the potential for drug exposure during pregnancy. Many drugs are beneficial for disease state management during pregnancy and provide significant fetal and maternal health benefits. However, a paucity of safety data combined with the imprecision of the current risk category system renders risk versus benefit assessment difficult. In response to decades of criticism, the U.S. Food and Drug Administration (FDA) is implementing a new pregnancy and lactation labeling rule designed to improve risk versus benefit assessment of drugs used in pregnant and nursing mothers. These recommendations will provide clear and detailed information for both patients and health care providers, and they will include three main categories: risk summary, clinical considerations, and data. The new labeling rules remove the previous letter risk categorization system (A, B, C, D, X). In this review, we summarize the upcoming FDA labeling changes and discuss their potential consequences on clinical practice. © 2014 Pharmacotherapy Publications, Inc. KEYWORDS: FDA; U.S. Food and Drug Administration; labeling; lactation; pregnancy; risk categories PMID 24390829

@@ Line 1: / Line 1: @@
+((Talk Page}}
 '''Links:''' [http://embryology.med.unsw.edu.au/Defect/drugs.htm Abnormal Development - Drugs] | [http://embryology.med.unsw.edu.au/Defect/drugs.htm#Australian_Fetal_Risk_Categories Australian Fetal Risk Categories] | [http://embryology.med.unsw.edu.au/Defect/drugs.htm#FDA_Fetal_Risk_Categories USA FDA Fetal Risk Categories] | [http://www.tga.gov.au/ Therapeutic Goods Authority] | [http://www.tga.gov.au/docs/html/adec/adec.htm Australian Drug Evaluation Committee (ADEC)] | [http://www.tga.gov.au/docs/html/medpreg.htm Prescribing Medicines in Pregnancy] | [http://www.tga.gov.au/docs/html/mip/exempt.htm Appendix A: Therapeutic goods exempted from pregnancy classification] |
+==2014==
+===Recent changes in pregnancy and lactation labeling: retirement of risk categories===
+Pharmacotherapy. 2014 Apr;34(4):389-95. doi: 10.1002/phar.1385. Epub 2014 Jan 4.
+Ramoz LL1, Patel-Shori NM.
+Abstract
+The rapid development and increased availability of novel pharmacologic therapies and pharmaceutical products has amplified the potential for drug exposure during pregnancy. Many drugs are beneficial for disease state management during pregnancy and provide significant fetal and maternal health benefits. However, a paucity of safety data combined with the imprecision of the current risk category system renders risk versus benefit assessment difficult. In response to decades of criticism, the U.S. Food and Drug Administration (FDA) is implementing a new pregnancy and lactation labeling rule designed to improve risk versus benefit assessment of drugs used in pregnant and nursing mothers. These recommendations will provide clear and detailed information for both patients and health care providers, and they will include three main categories: risk summary, clinical considerations, and data. The new labeling rules remove the previous letter risk categorization system (A, B, C, D, X). In this review, we summarize the upcoming FDA labeling changes and discuss their potential consequences on clinical practice.
+© 2014 Pharmacotherapy Publications, Inc.
+KEYWORDS:
+FDA; U.S. Food and Drug Administration; labeling; lactation; pregnancy; risk categories
+PMID 24390829